Trial · NCT02506153
Adverse events382
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 382
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | FDA Approved Regimen | 129 | 565 | |
| other | Anemia | Blood and lymphatic system disorders | MK-3475 (Pembrolizumab) | 115 | 639 | |
| other | Adrenal insufficiency | Endocrine disorders | FDA Approved Regimen | 29 | 565 | |
| other | Adrenal insufficiency | Endocrine disorders | MK-3475 (Pembrolizumab) | 22 | 639 | |
| other | Endocrine disorders-Other | Endocrine disorders | FDA Approved Regimen | 52 | 565 | |
| other | Endocrine disorders-Other | Endocrine disorders | MK-3475 (Pembrolizumab) | 28 | 639 | |
| other | Hyperthyroidism | Endocrine disorders | FDA Approved Regimen | 19 | 565 | |
| other | Hyperthyroidism | Endocrine disorders | MK-3475 (Pembrolizumab) | 54 | 639 | |
| other | Hypothyroidism | Endocrine disorders | FDA Approved Regimen | 69 | 565 | |
| other | Hypothyroidism | Endocrine disorders | MK-3475 (Pembrolizumab) | 143 | 639 | |
| other | Blurred vision | Eye disorders | FDA Approved Regimen | 36 | 565 | |
| other | Blurred vision | Eye disorders | MK-3475 (Pembrolizumab) | 33 | 639 | |
| other | Eye disorders-Other | Eye disorders | FDA Approved Regimen | 34 | 565 | |
| other | Eye disorders-Other | Eye disorders | MK-3475 (Pembrolizumab) | 29 | 639 | |
| other | Abdominal pain | Gastrointestinal disorders | FDA Approved Regimen | 106 | 565 | |
| other | Abdominal pain | Gastrointestinal disorders | MK-3475 (Pembrolizumab) | 87 | 639 | |
| other | Colitis | Gastrointestinal disorders | FDA Approved Regimen | 54 | 565 | |
| other | Colitis | Gastrointestinal disorders | MK-3475 (Pembrolizumab) | 13 | 639 | |
| other | Constipation | Gastrointestinal disorders | FDA Approved Regimen | 103 | 565 | |
| other | Constipation | Gastrointestinal disorders | MK-3475 (Pembrolizumab) | 103 | 639 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02506153/events